Your browser is no longer supported. Please, upgrade your browser.
Settings
LH [NYSE]
Laboratory Corporation of America Holdings
IndexS&P 500 P/E11.01 EPS (ttm)26.90 Insider Own0.20% Shs Outstand98.50M Perf Week4.36%
Market Cap28.66B Forward P/E18.47 EPS next Y16.04 Insider Trans-6.79% Shs Float97.13M Perf Month7.36%
Income2.64B PEG- EPS next Q5.57 Inst Own93.50% Short Float1.63% Perf Quarter11.39%
Sales15.32B P/S1.87 EPS this Y90.00% Inst Trans0.32% Short Ratio2.34 Perf Half Y29.37%
Book/sh101.74 P/B2.91 EPS next Y-28.84% ROA13.70% Target Price303.83 Perf Year52.00%
Cash/sh19.54 P/C15.16 EPS next 5Y-11.00% ROE30.20% 52W Range170.05 - 296.10 Perf YTD45.49%
Dividend- P/FCF10.54 EPS past 5Y29.60% ROI12.10% 52W High0.02% Beta1.04
Dividend %- Quick Ratio1.50 Sales past 5Y10.00% Gross Margin38.00% 52W Low74.15% ATR4.93
Employees72400 Current Ratio1.70 Sales Q/Q47.40% Oper. Margin24.50% RSI (14)76.07 Volatility2.03% 1.61%
OptionableYes Debt/Eq0.55 EPS Q/Q339.40% Profit Margin17.30% Rel Volume0.95 Prev Close294.66
ShortableYes LT Debt/Eq0.50 EarningsJul 29 BMO Payout0.00% Avg Volume677.78K Price296.15
Recom1.70 SMA205.73% SMA508.95% SMA20023.68% Volume645,176 Change0.51%
Jan-11-21Upgrade Argus Hold → Buy $245
Jan-11-21Downgrade Wolfe Research Peer Perform → Underperform
Jan-08-21Downgrade Wolfe Research Outperform → Peer Perform
Jul-14-20Upgrade BofA Securities Neutral → Buy $194 → $220
Jul-13-20Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20Resumed Deutsche Bank Buy $210
May-15-20Upgrade Mizuho Neutral → Buy $158 → $186
Apr-29-20Downgrade KeyBanc Capital Markets Overweight → Sector Weight
Apr-27-20Upgrade Wolfe Research Underperform → Peer Perform
Apr-27-20Upgrade Citigroup Neutral → Buy $204 → $214
Jan-08-20Initiated Wells Fargo Overweight $210
Jul-16-19Upgrade BofA/Merrill Underperform → Neutral
Jun-21-19Upgrade Deutsche Bank Hold → Buy $180 → $220
Apr-02-19Upgrade Jefferies Hold → Buy $154 → $190
Jan-17-19Initiated UBS Buy $169
Jan-03-19Downgrade BofA/Merrill Neutral → Underperform
Dec-03-18Downgrade Craig Hallum Buy → Hold
Oct-30-18Downgrade Argus Buy → Hold
Oct-25-18Downgrade Canaccord Genuity Buy → Hold $190 → $162
Oct-19-18Resumed BofA/Merrill Buy
Jul-31-21 10:07AM  
Jul-30-21 12:49PM  
12:35PM  
11:54AM  
10:33AM  
10:28AM  
10:24AM  
10:22AM  
09:13AM  
09:11AM  
09:09AM  
05:38AM  
Jul-29-21 03:00PM  
10:38AM  
08:25AM  
07:21AM  
07:01AM  
Jul-28-21 01:18PM  
08:00AM  
Jul-26-21 09:15AM  
07:00AM  
Jul-23-21 12:10PM  
09:17AM  
07:01AM  
Jul-22-21 03:03PM  
07:54AM  
Jul-21-21 07:35AM  
Jul-20-21 06:59AM  
Jul-19-21 08:50AM  
Jul-16-21 11:50AM  
11:40AM  
08:41AM  
Jul-15-21 08:27AM  
Jul-14-21 07:51AM  
Jul-12-21 08:15AM  
08:14AM  
Jul-08-21 09:15AM  
06:39AM  
Jul-05-21 07:51AM  
Jul-02-21 06:59AM  
Jul-01-21 05:03PM  
Jun-30-21 11:50AM  
11:40AM  
04:22AM  
Jun-28-21 11:30AM  
08:50AM  
Jun-26-21 07:36AM  
Jun-24-21 10:28AM  
Jun-23-21 04:40PM  
04:36PM  
Jun-22-21 08:28AM  
Jun-18-21 06:20AM  
Jun-16-21 04:42PM  
Jun-15-21 07:32AM  
Jun-14-21 11:11AM  
Jun-09-21 11:47AM  
Jun-08-21 04:35PM  
Jun-03-21 07:14PM  
Jun-02-21 05:20PM  
May-31-21 03:30AM  
May-28-21 09:10AM  
09:00AM  
May-25-21 03:56PM  
May-24-21 05:14PM  
May-21-21 06:10PM  
01:54PM  
May-20-21 12:48PM  
09:20AM  
May-19-21 05:54PM  
May-18-21 09:27AM  
06:59AM  
May-14-21 10:10AM  
09:50AM  
May-13-21 08:57AM  
May-12-21 08:14PM  
06:57AM  
May-11-21 04:18PM  
May-05-21 10:54AM  
May-04-21 11:04AM  
May-03-21 04:05PM  
06:58AM  
May-01-21 11:00AM  
Apr-30-21 06:04AM  
Apr-29-21 11:59AM  
08:15AM  
06:56AM  
06:45AM  
Apr-28-21 09:13AM  
08:09AM  
Apr-23-21 08:26AM  
Apr-22-21 12:33PM  
12:10PM  
11:58AM  
Apr-20-21 04:13PM  
07:55AM  
Apr-19-21 09:49AM  
09:00AM  
Apr-18-21 06:07PM  
Apr-16-21 07:01AM  
Apr-03-21 10:56AM  
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
van der Vaart Sandra DEVP, Chief Legal OfficerJun 07Option Exercise84.864,500381,8709,737Jun 09 02:03 PM
van der Vaart Sandra DEVP, Chief Legal OfficerJun 07Sale266.564,5001,199,5205,237Jun 09 02:03 PM
Kirchgraber Paul RCEO, Covance Drug DevelopmentMay 06Sale276.552,500691,3757,844May 10 08:21 AM
BELINGARD JEAN-LUCDirectorMay 03Option Exercise98.492,600256,07418,169May 05 10:48 AM
BELINGARD JEAN-LUCDirectorMay 03Sale269.162,600699,80315,569May 05 10:48 AM
van der Vaart Sandra DEVP, Chief Legal OfficerMar 30Sale251.88812204,5275,237Apr 01 08:32 AM
Schroeder Mark SEVP, President-Diagnostics LabMar 30Sale251.88667168,0045,006Apr 01 08:32 AM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Option Exercise157.092,166340,2512,660Feb 19 02:17 PM
Wilkinson Peter JSVP, Chief Accounting OfficerFeb 18Sale241.512,317559,589343Feb 19 02:17 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 16Sale236.5520849,2024,426Feb 17 04:28 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 16Sale237.0618844,5674,339Feb 17 04:27 PM
van der Vaart Sandra DEVP, Chief Legal OfficerFeb 05Sale225.8510924,6184,219Feb 08 03:43 PM
Schroeder Mark SEVP, President-Diagnostics LabFeb 05Sale225.8520345,8484,152Feb 08 03:40 PM
Williams R SandersDirectorJan 26Option Exercise98.491,300128,0375,246Jan 28 12:11 PM
Schroeder Mark SEVP, President-Diagnostics LabNov 06Sale214.59588126,1793,949Nov 10 10:48 AM
Kirchgraber Paul RCEO, Covance Drug DevelopmentNov 04Sale214.141,500321,2047,698Nov 06 09:06 AM